OptiNose Inc (OPTN) Actualités

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million

YARDLEY, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on...

Form 8-K - Current report

Optinose Announces 1-for-15 Reverse Stock Split

YARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (NASDAQ: OPTN), a pharmaceutical company...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form DEF 14A - Other definitive proxy statements

Form PRE 14A - Other preliminary proxy statements

Optinose to Present at the Piper Sandler 36th Annual Healthcare Conference

YARDLEY, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on...

Form DEF 14A - Other definitive proxy statements

Form 10-Q - Quarterly report [Sections 13 or 15(d)]